Maravai LifeSciences Holdings, Inc. sets its IPO terms.

Maravai LifeSciences Holdings, Inc.’s (MRVI) IPO will take place on November 19, 2020. Maravai LifeSciences is a leading life sciences company that provides essential products for the development of drug therapies, diagnostics and novel vaccines and supporting research on human diseases. As of September 3, 2020 Maravai has over 5000 clients, including 20 of the world’s leading biopharmaceutical companies as well as leading academic research institutions. The company’s products are targeted at key steps in biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications, antibody products for the detection of impurities during the production of biopharmaceuticals products and products for the detection of protein expression in tissues of various species.
The company’s estimated value after its IPO will be US$6.8 billion.
Listed underwriters of the IPO are Morgan Stanley, Jefferies, Goldman Sachs, BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, KeyBanc Capital Markets, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners.